Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Solid Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,545 result(s) found for: Solid Tumor. Displaying page 1 of 78.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-004395-34 Sponsor Protocol Number: C4221026 Start Date*: 2022-04-25
    Sponsor Name:Pfizer Inc.
    Full Title: ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES
    Medical condition: solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005190-36 Sponsor Protocol Number: 20050252 Start Date*: 2015-01-22
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors
    Medical condition: Solid Tumours
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065147 Malignant solid tumor LLT
    17.1 100000004864 10065252 Solid tumor LLT
    17.1 100000004864 10049280 Solid tumour LLT
    17.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001596-14 Sponsor Protocol Number: TYR300-101 Start Date*: 2023-06-26
    Sponsor Name:Tyra Biosciences, Inc.
    Full Title: A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF 301)
    Medical condition: Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001403-33 Sponsor Protocol Number: TCTLR-101 Start Date*: 2023-06-06
    Sponsor Name:Ascendis Pharma Oncology Division A/S
    Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor...
    Medical condition: Locally advanced or metastatic solid tumor malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Trial now transitioned) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002980-81 Sponsor Protocol Number: CO-3810-101 Start Date*: 2021-02-10
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor
    Medical condition: Advanced gynecological solid tumor
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002505-11 Sponsor Protocol Number: CA009-002 Start Date*: 2016-06-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal A...
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001155-39 Sponsor Protocol Number: D8480C00016 Start Date*: 2012-03-09
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I trial of AZD2171, an orally bioavailable antiangiogenic agent, in children and adolescents with refactory or recurrent solid tumours or acute myelogenous leukemia
    Medical condition: Refractory or recurrent solid tumours or acute myelogenous leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000157-27 Sponsor Protocol Number: INCB86550-203 Start Date*: 2020-08-25
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors
    Medical condition: Immune Checkpoint Inhibitor–Naïve Selected Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-001093-34 Sponsor Protocol Number: ONC-2014-001 Start Date*: 2014-11-25
    Sponsor Name:Istituto Clinico Humanitas
    Full Title: An Open-Label Phase II Study of regorafenib In Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND
    Medical condition: Metastatic Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000597-11 Sponsor Protocol Number: CA022-001 Start Date*: 2018-07-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) DE (Prematurely Ended) BE (Completed) NO (Completed) NL (Completed) PL (Prematurely Ended) FI (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000509-29 Sponsor Protocol Number: GCT1042-02 Start Date*: 2022-11-04
    Sponsor Name:Genmab A/S
    Full Title: A Phase 1/2, Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
    Medical condition: Metastatic Solid Malignant tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002009-31 Sponsor Protocol Number: MO25757 Start Date*: 2012-03-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A single arm open label multicentre extension study of bevacizumab in patients with solid tumours on study treatment with bevacizumab at the end of a F. Hoffmann-La Roche and/or Genentech sponsored...
    Medical condition: Solid tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) ES (Completed) SK (Completed) NL (Completed) FR (Completed) IT (Prematurely Ended) DE (Completed) EE (Completed) HU (Completed) LV (Prematurely Ended) AT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000416-21 Sponsor Protocol Number: CA030-001 Start Date*: 2019-01-31
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) DE (Completed) PL (Completed) FI (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005605-27 Sponsor Protocol Number: TNG908-C101 Start Date*: 2022-09-07
    Sponsor Name:Tango Therapeutics, Inc.
    Full Title: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
    Medical condition: Phase 1: • Locally advanced or metastatic MTAP-deleted solid tumors (with the exception of gliomas) Phase 2: • Arm 1: Locally advanced or metastatic MTAP-deleted squamous and nonsquamous NSCLC ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    24.0 100000004864 10085300 Squamous non-small cell lung cancer LLT
    21.0 100000004864 10027408 Mesothelioma malignant advanced LLT
    21.0 100000004864 10027409 Mesothelioma malignant localised LLT
    21.1 100000004864 10026667 Malignant peripheral nerve sheath tumor LLT
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    21.1 100000004864 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024237-23 Sponsor Protocol Number: CDI-CS-001 Start Date*: 2011-05-06
    Sponsor Name:Basilea Pharmaceutica International Ltd.
    Full Title: An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors
    Medical condition: Advanced or recurrent solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003912-11 Sponsor Protocol Number: Sym015-01 Start Date*: 2017-03-10
    Sponsor Name:Symphogen A/S
    Full Title: An Open-label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients with...
    Medical condition: Advanced Solid Tumor Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005806-12 Sponsor Protocol Number: CBLZ945X2101 Start Date*: 2016-10-20
    Sponsor Name:Novartis Farmaceútica S.A.
    Full Title: A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003385-84 Sponsor Protocol Number: GO40782(RXDX-101-02) Start Date*: 2016-03-15
    Sponsor Name:F. Hoffman-La Roche Ltf
    Full Title: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRA...
    Medical condition: Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003998-26 Sponsor Protocol Number: GCT1044-01 Start Date*: 2020-05-16
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumors
    Medical condition: Malignant Solid Tumors, per protocol GCT1044-01
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002370-31 Sponsor Protocol Number: IMA203-101 Start Date*: 2020-03-10
    Sponsor Name:Immatics US InC
    Full Title: Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients wi...
    Medical condition: Recurrent and / or refractory solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 09:02:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA